The Israeli drugmaker said its generic EpiPen is now available in limited supply in the United States.
It said that additional supply, as well as a generic version of the lower-dose EpiPen Jr., will be available next year.
There has been a shortage of Mylan's EpiPens, which dominate the allergy market, since at least May.
The company has blamed manufacturing issues at a Pfizer plant, which supplies the EpiPens, for the shortage.
The FDA approved Teva's version of EpiPen in August.
EpiPen autoinjectors deliver a dose of epinephrine in the event of severe allergic reaction, such as to bee stings or exposure to peanuts.